Forxiga is the first and only SGLT2i approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).5
Forxiga is the first and only SGLT2i approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).5
In patients with HFrEF (NYHA, class II-IV)# and eGFR ≥30 mL/min/1.73m², Forxiga has been shown to offer early efficacy†, quality-of-life improvement versus placebo and once-daily dosing with no uptitration.1,2,4,5*
DAPA HF Trial Overview
Hear Professor Mark Petrie, Professor of Cardiology at the University of Glasgow, discuss the the design and results of the DAPA-HF Trial.
Heart failure: a call to action
Professor Martin Cowie discusses strategies to improve
heart failure care in the UK.
In patients with HFrEF (NYHA, class II-IV)# and eGFR ≥30 mL/min/1.73m², Forxiga has been shown to offer early efficacy†, quality-of-life improvement versus placebo and once-daily dosing with no uptitration.1,2,4,5*
The Landmark DAPA-HF Trial1,6
DAPA-HF is the first heart failure (HFrEF) outcomes study with an SGLT2i. The trial enrolled 4744 patients with HFrEF (NYHA class II-IV)#, with and without T2D.
On top of standard of care
Forxiga reduces the risk of CV death or worsening HF1
Primary endpoint: Composite of CV death or worsening HF1*
Adapted from McMurray et al. 2019.
Significant Reductions in Each Component of the Primary Endpoint
On top of standard of care, Forxiga 10 mg achieved a statistically significant reduction in each component of the primary endpoint1
Adapted from McMurray et al. 2019.
Prespecified Subgroup Analysis of Patients With and Without T2D1,3
On top of standard of care, Forxiga demonstrated proven efficacy in patients with and without T2D.1,3
Adapted from Petrie et al. 2020.
On top of standard of care, Forxiga 10 mg
reduces the risk of all-cause mortality1‡
Adapted from McMurray et al. 2019.
See the NICE Technology Appraisal
Guidance for Forxiga in HFrEF here
Forxiga 10 mg has a Well-Established Safety Profile1,5,9
Over 8 years of experience since first approval in T2D5
The overall safety profile of dapagliflozin in patients with heart failure was consistent with the known safety profile of dapagliflozin1,5
When prescribing in patients with co-morbid symptomatic HFrEF and insufficiently controlled T2D5
Simple once-daily dosing††, no dose adjustment required based on renal function.
†† No dose adjustment is necessary for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, the dose may be increased to 10 mg5